OTCMKTS:HCYTD H-CYTE (HCYTD) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free HCYTD Stock Alerts $2.02 -1.98 (-49.50%) (As of 07/11/2022) Add Compare Share Share Today's Range$2.02▼$2.7750-Day Range$2.02▼$2.0252-Week Range$2.02▼$77.00Volume400 shsAverage Volume103 shsMarket Capitalization$521,160.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get H-CYTE alerts: Email Address Ad Stansberry ResearchHow to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."Get the full story here. About H-CYTE Stock (OTCMKTS:HCYTD)H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.Read More HCYTD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HCYTD Stock News HeadlinesApril 23, 2024 | americanbankingnews.comH-CYTE (OTCMKTS:HCYTD) Stock Price Down 49.5%April 12, 2024 | cbsnews.comThe best H&R Block DIY income tax filing options for last-minute filers in 2024April 25, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."March 1, 2024 | cnet.comH&R Block Review 2024: The Best Free Online Tax Filing ExperienceFebruary 14, 2024 | forbes.comH&R Block Coupons February 2024November 2, 2023 | morningstar.comHyatt Hotels Corp Class A HJune 14, 2023 | forbes.comH-E-B Grocery CompanyMay 12, 2023 | marketwatch.com10-K: H-CYTE, INC.April 25, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."March 24, 2023 | seekingalpha.comHCYT H-CYTE, Inc.September 8, 2022 | finance.yahoo.comH-CYTE Completes Acquisition of JantibodyJuly 23, 2022 | apnews.comH-CYTE to Expect the Completed Acquisition of Jantibody Within 30 DaysJune 13, 2022 | finance.yahoo.comH-CYTE Announces 1-for-1,000 Reverse Stock SplitMarch 6, 2022 | yahoo.comShould You Refrigerate Peanut Butter?March 6, 2022 | yahoo.comNetflix’s new superhero show might be the weirdest thing you ever watchMarch 4, 2022 | finance.yahoo.comH-CYTE Announces Proceeds of $1.05 Million from Warrant ExerciseFebruary 7, 2022 | nasdaq.comH-CYTE Inc (HCYT)January 11, 2022 | seekingalpha.comH-CYTE signs letter of intent to acquire Catheter PrecisionJanuary 11, 2022 | finance.yahoo.comH-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.December 6, 2021 | finance.yahoo.comH-CYTE Names Michael Yurkowsky Chief Executive OfficerSeptember 9, 2021 | au.finance.yahoo.comItalian court seeks opinion on Berlusconi's health due to trial delaysSeptember 8, 2021 | finance.yahoo.comH-CYTE Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory HealthSee More Headlines Receive HCYTD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolOTCMKTS:HCYTD CUSIPN/A CIK1591165 Webwww.hcyte.com Phone(844) 633-6839FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,800,000.00 Net Margins-450.40% Pretax Margin-450.40% Return on EquityN/A Return on Assets-777.68% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual Sales$1.61 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value($31.45) per share Price / Book-0.06Miscellaneous Outstanding Shares258,000Free Float244,000Market Cap$521,160.00 OptionableNot Optionable Beta1.12 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Michael W. Yurkowsky (Age 50)CEO & Director Comp: $180kMr. Jeremy Daniel (Age 46)Chief Financial Officer Comp: $200kDr. Tanya Rhodes Ph.D. (Age 61)Chief Scientific Officer Comp: $252kMr. Jeffery Wright CPA (Age 39)CPA, Controller & Principal Accounting Officer Key CompetitorsMotus GINASDAQ:MOTSQuantRx BiomedicalOTCMKTS:QTXBPresbiaOTCMKTS:LENSFSintx TechnologiesNASDAQ:SINTRegenicinOTCMKTS:RGINView All Competitors HCYTD Stock Analysis - Frequently Asked Questions How have HCYTD shares performed in 2024? H-CYTE's stock was trading at $2.02 at the start of the year. Since then, HCYTD stock has increased by 0.0% and is now trading at $2.02. View the best growth stocks for 2024 here. How do I buy shares of H-CYTE? Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:HCYTD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport Society1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding H-CYTE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
